The formation of the menopause economy
How the menopause category went from invisible to a multi-billion-dollar formation in less than five years.
Executive summary
How the menopause category went from invisible to a multi-billion-dollar formation in less than five years. Executive Summary Menopause is transitioning from a medical symptom to an economic sector—creating a $24.4B+ market spanning pharmaceuticals, digital health, supplements, devices, workplace benefits, and consumer goods. OVUM reads this as a category signal for hormonal health, menopause care, and lifecycle medicine, with implications for product strategy, coverage design, and capital allocation.
Key findings
- Executive Summary Menopause is transitioning from a medical symptom to an economic sector—creating a $24.4B+ market spanning pharmaceuticals, digital health, supplements, devices, workplace benefits, and consumer goods.
- This sector formation is driven by three forces: (1) regulatory tailwinds (FDA removing HRT black box warnings, approving non-hormonal drugs), (2) employer recognition that menopause directly impacts workforce productivity and retention, and (3) consumer willingness to spend on symptom relief and health optimization.
- The menopause economy is fragmenting into distinct sub-markets with different winners: pharma (Astellas, Bayer, Gedeon Richter), virtual care (Midi Health, Gennev, Elektra Health), supplements (Stripes, Wile, Valerie), devices (Embr Labs, Oura), and workplace benefits (Evela Health, Peppy).
- Companies that build integrated menopause ecosystems spanning diagnosis, treatment, and lifestyle optimization will capture disproportionate value.
Market implications
- Menopause care is being reframed as midlife cardiometabolic, cognitive, and musculoskeletal risk management — expanding the addressable market well beyond symptom relief.
- Employers are the fastest-moving buyer, using menopause benefits as a retention and productivity lever for a workforce cohort that was previously invisible.
- Clinical guideline movement (HRT re-evaluation, non-hormonal options) is opening pharmaceutical and D2C lanes simultaneously.
Interpretative layer
Professional access includes investor relevance, OVUM view, and category-level implications.
Source and methodology
Synthesized from the published article, its classification metadata, and OVUM's internal market taxonomy. Last indexed Feb 28, 2026.
Full analysis
Executive Summary Menopause is transitioning from a medical symptom to an economic sector—creating a $24.4B+ market spanning pharmaceuticals, digital health, supplements, devices, workplace benefits, and consumer goods. This sector formation is driven by three forces: (1) regulatory tailwinds (FDA removing HRT black box warnings, approving non-hormonal drugs), (2) employer recognition that menopause directly impacts workforce productivity and retention, and (3) consumer willingness to spend on symptom relief and health optimization. The menopause economy is fragmenting into distinct sub-markets with different winners: pharma (Astellas, Bayer, Gedeon Richter), virtual care (Midi Health, Gennev, Elektra Health), supplements (Stripes, Wile, Valerie), devices (Embr Labs, Oura), and workplace benefits (Evela Health, Peppy). Companies that build integrated menopause ecosystems spanning diagnosis, treatment, and lifestyle optimization will capture disproportionate value.
Part 1: Market Size and Fragmentation The Menopause Economy Emerges Menopause affects 1.3M US women annually; 1B+ women globally entering postmenopause by 2030. Women's wellness spend projected to exceed $460B by 2030; menopause represents 5-6% of this market ($24.4B+). Market Fragmentation by Segment
Total Addressable Market: $24.4B+ by 2030; growing 15-25% annually.
“Total Addressable Market: $24.4B+ by 2030; growing 15-25% annually.”
Part 2: Pharmaceutical Segment—Non-Hormonal Drugs Reshape Market The NK3 Antagonist Revolution For 50+ years, HRT was the only pharmaceutical option for menopause. Non-hormonal drugs are now disrupting this market: Astellas Veozah (fezolinetant, NK3 antagonist): FDA approved May 2023; ¥33.8B FY2024 revenue (~$220M); FY2025 target ¥50B (~$330M); first-to-market advantage Bayer Lynkuet (elinzanetant, NK3 antagonist): FDA approved Oct 2025; peak sales forecast $1B+; competing directly with Veozah Gedeon Richter Ryeqo (GnRH antagonist): EU approved; NHS England approved Mar 2025; dual indication (endometriosis + menopause VMS); HUF 928.96B 2025 revenue (+8.3% YoY) Pfizer Myfembree (relugolix combination): FDA approved; co-developed with Myovant; GnRH antagonist approach Competitive Dynamics Veozah vs Lynkuet: Both NK3 antagonists; Veozah has 2.5-year head start; Lynkuet competing on efficacy/safety differentiation NK3 vs GnRH antagonists: Different mechanisms; NK3 (Veozah, Lynkuet) vs GnRH (Ryeqo, Myfembree); both effective but different side effect profiles Pharma vs Virtual Care: Non-hormonal drugs reduce demand for HRT-centric virtual care platforms; creates opportunity for platforms offering non-hormonal options Implication: Pharma segment is consolidating around 2-3 major players; non-hormonal drugs expanding addressable market (women who cannot/will not use HRT).
Continue reading full analysis (8 more sections) →Collapse full analysis ↑
Part 3: Virtual Care Segment—Insurance Coverage Drives Scale Insurance-Covered Menopause Platforms Midi Health ($254M, unicorn): All 50 states; Aetna, BCBS, Cigna, Humana, UnitedHealthcare; $150M revenue run rate; 230K+ patients; 91% symptom improvement within 2 months Gennev: Aetna-covered nationwide; first-mover advantage; sexual health integration; early-stage menopause telehealth pioneer Elektra Health: ACA health plan model (HelloMeno with Oscar Health, Jan 2026, 11 states); innovative insurance integration; whole-person care Alloy Women's Health ($16M Series A): Nationwide US; personalized HRT + supplements; growing employer partnerships Evernow ($52.5M): DTC HRT subscription; celebrity backing (Paltrow, Barrymore, Diaz); Clearblue partnership (Jan 2025); mostly cash-pay DTC Menopause Platforms Winona: Bioidentical hormones focus; DTC telehealth; growing consumer brand HerMD: Hybrid (in-person + virtual); sexual health integration; bio-psycho-social model Stella: Holistic care (HRT + lifestyle + mental health); early stage; whole-person approach Competitive Dynamics Insurance vs DTC: Insurance-covered platforms (Midi Health, Gennev) achieve superior unit economics; DTC platforms (Evernow, Winona) build consumer brand Specialization vs Breadth: Midi Health expanding to "every life stage"; Gennev maintaining menopause focus; both strategies viable Pharma Integration: Virtual care platforms increasingly partnering with pharma (Evernow + Clearblue) to offer integrated diagnosis + treatment Implication: Virtual care segment consolidating around 2-3 major insurance-covered platforms; DTC platforms remain niche but profitable.
Part 4: Supplements and Wellness Segment—Celebrity Brands Drive Mainstream Adoption Menopause-Specific Supplement Brands Stripes Beauty (Naomi Watts-founded): Menopause products + education; DTC e-commerce; lifestyle brand; destigmatizes menopause Wile ($3M seed): Perimenopause supplements + stress management; plant-based; targets stress + hormones as integrated problem Valerie (£514K pre-seed May 2025): Perimenopause-targeted supplements; 45% women investors; targeting employer benefits channel Perelel ($37.7M + $27M growth): Life-stage nutrition for women; perimenopause and menopause-specific formulations; subscription model Timeline ($141M+ Series D): Mitochondrial longevity supplements; cellular health focus; strategic investor backing Perimenopause-Specific Brands Wile: Stress + hormones integration; plant-based; early-stage but growing Valerie: Perimenopause-targeted; targeting employer benefits; emerging brand Perelel: Life-stage approach; perimenopause as distinct phase; subscription model Competitive Dynamics Celebrity vs Science: Stripes (celebrity-founded) vs Wile (science-backed); both strategies work; celebrity drives mainstream awareness DTC vs Retail: Stripes and Wile primarily DTC; Perelel expanding into retail; retail distribution increases accessibility Supplement vs Pharmaceutical: Supplements address mild-to-moderate symptoms; pharma addresses moderate-to-severe symptoms; complementary markets Implication: Supplement segment consolidating around celebrity-backed brands; employer benefits channel emerging as key distribution.
Part 5: Devices Segment—Wearables and Thermal Therapy Hot Flash-Specific Devices Embr Labs: Wearable thermal therapy (wrist cooling/warming); FDA-cleared; market pioneer in VMS wearables; addresses hot flashes directly identifyHer: Menopause tracker wearable; vasomotor indicator assessment; AI-powered app; Ireland-based femtech startup General Health Wearables with Menopause Features Oura Ring ($200M+ funded): 24/7 sleep, HRV, temperature monitoring; enables early illness detection; used in menopause research Apple Watch: Menstrual cycle tracking, ECG, irregular rhythm detection; enables cardiovascular health monitoring during menopause Garmin: Menstrual cycle tracking, pregnancy tracking, body battery, stress tracking; enables energy and symptom correlation Withings: Smart scales, BP monitors, sleep tracking; medical-grade; enables cardiometabolic monitoring during menopause Competitive Dynamics Specialized vs General: Embr Labs (hot flash-specific) vs Oura/Apple (general health); specialized devices address specific symptoms; general wearables provide comprehensive health picture Hardware vs Software: Embr Labs (hardware-centric) vs Oura (hardware + SaaS); hardware creates moat but requires manufacturing; SaaS enables scale Clinical vs Consumer: Embr Labs (FDA-cleared) vs Oura (consumer wellness); clinical validation enables premium pricing and payer coverage Implication: Device segment fragmenting into specialized (hot flash) and general (health monitoring); both strategies viable.
Part 6: Workplace Benefits Segment—Rapid Employer Adoption Menopause Benefits Adoption Trajectory 4% of employers (2023) → 15% (2024) → projected 25%+ (2026) Employers recognize menopause symptoms directly impact productivity, retention, and healthcare costs Federal excepted benefits rule (proposed 2025-26) lowers barriers for small employers Employer Menopause Benefits Platforms Evela Health: Menopause care via employer benefits; B2B employer platform; web app for female employees 40+; personalized care plans Peppy: Employee menopause + fertility + MSK; enterprise focus; multidisciplinary approach Maven Clinic: Full-stack women's health (fertility → menopause); employer partnerships; thousands of employers Midi Health: Expanding employer channel; Fortune 100 partnerships; menopause as retention tool Valerie: Perimenopause supplements; targeting employer benefits channel; emerging distribution model Employer Value Proposition Retention: Menopause benefits reduce turnover among high-value midlife female employees Productivity: Symptom relief (hot flashes, insomnia, brain fog) improves presenteeism and engagement Healthcare costs: Preventive menopause care reduces downstream complications and emergency care utilization DEI: Menopause benefits signal commitment to women's health and midlife workforce support Competitive Dynamics Specialized vs Broad: Evela (menopause-only) vs Maven (full lifecycle); both strategies viable; specialized platforms build deeper expertise B2B vs B2C: Employer-facing platforms (Evela, Peppy) vs consumer-facing platforms (Evernow, Stripes); different go-to-market strategies Integration: Platforms integrating menopause with fertility (Maven, Peppy) capture higher employee LTV Implication: Workplace benefits segment is fastest-growing; employer adoption accelerating; multiple platforms can coexist.
Part 7: Diagnostics Segment—Continuous Hormone Monitoring Menopause-Specific Diagnostics Hormona ($6.7M seed May 2025): Monthly urine hormone testing (estrogen, progesterone, FSH); 90%+ accuracy vs venous blood; AI pattern analysis; 2M+ data points Hertility ($16.3M Series A May 2025): 10-hormone panel; cycle-specific recommendations; comprehensive testing Oova ($10.3M Series A): Quantitative urine hormone testing; Mount Sinai spinout; addresses irregular cycle monitoring Mira Care (bootstrapped): Urine hormone testing (LH/E3G/PdG/FSH); 99% accuracy; Oura integration 2025; CES 2026 award InsideTracker: Blood biomarkers + DNA + wearable integration; "InnerAge" biological age score; enables tracking aging rate Competitive Dynamics Quantitative vs Qualitative: Quantitative testing (Hormona, Hertility, Oova, Mira) vs qualitative symptom tracking; quantitative enables personalized dosing At-Home vs Lab: At-home testing (Hormona, Oova, Mira) vs traditional lab testing; at-home improves accessibility and frequency Standalone vs Integrated: Standalone diagnostics (Hormona, Hertility) vs integrated platforms (InsideTracker + wearables); integration creates network effects Implication: Diagnostics segment consolidating around continuous monitoring; at-home testing enabling personalized menopause care.
Part 8: Integrated Menopause Ecosystems The Ecosystem Advantage Companies integrating diagnosis, treatment, and lifestyle optimization capture disproportionate value: Midi Health: Virtual care + insurance coverage + outcomes data + employer partnerships + supplement line (Aug 2025) + AgeWell longevity product (May 2025) Maven Clinic: Virtual care + diagnostics + employer benefits + full lifecycle (fertility → menopause) Elektra Health: Virtual care + ACA health plan + primary care integration + cardiology coordination Evernow: Virtual care + HRT delivery + Clearblue partnership (diagnostics) + Talkspace partnership (mental health) Ecosystem Benefits Higher LTV: Integrated ecosystems capture more of patient healthcare spend Better Outcomes: Integrated care (medical + lifestyle + mental health) produces superior outcomes Defensible Positioning: Ecosystems create switching costs; patients don't want to re-enter fragmented care Data Moats: Integrated data (medical, lifestyle, biomarkers) enables proprietary insights Implication: Menopause economy consolidating around integrated ecosystems; point solutions remain niche.
Part 9: Investment Implications Thesis 1: Menopause Economy Achieves Venture Scale - Midi Health ($1B+ unicorn), Maven Clinic (unicorn), Evernow ($52.5M), Hormona ($6.7M seed May 2025), Stripes (growth-stage) - Menopause platforms achieve venture-scale returns via insurance coverage + employer adoption + consumer spending Thesis 2: Regulatory Tailwinds Accelerate Growth - FDA removes HRT black box warnings; approves non-hormonal drugs (Veozah, Lynkuet); federal excepted benefits rule lowers employer barriers - Favorable regulatory environment accelerates adoption across all segments Thesis 3: Employer Adoption Is Fastest-Growing Channel - Menopause benefits: 4% (2023) → 15% (2024) → 25%+ (2026); fastest-growing segment - Employer-facing platforms (Evela Health, Peppy, Valerie) well-positioned for rapid growth Thesis 4: Integrated Ecosystems Win - Midi Health (virtual care + supplements + longevity), Maven Clinic (full lifecycle), Elektra Health (health plan integration), Evernow (care + partnerships) - Platforms integrating diagnosis, treatment, and lifestyle capture disproportionate value Thesis 5: Multiple Business Models Succeed - Pharma (Astellas, Bayer), Virtual care (Midi Health, Gennev), Supplements (Stripes, Wile), Devices (Embr Labs), Workplace benefits (Evela Health) - Not winner-take-all; multiple models coexist Thesis 6: Celebrity Backing Drives Mainstream Adoption - Stripes (Naomi Watts), Evernow (Paltrow, Barrymore, Diaz), Wile (Judy Greer) - Celebrity founders drive mainstream awareness and consumer adoption
Conclusion Menopause is forming as a distinct economic sector ($24.4B+ market) fragmenting into pharma, virtual care, supplements, devices, workplace benefits, and diagnostics. Regulatory tailwinds (HRT black box warning removal, non-hormonal drug approvals, federal excepted benefits rule) and employer adoption acceleration create favorable market conditions. Companies building integrated menopause ecosystems spanning diagnosis, treatment, and lifestyle optimization will capture disproportionate value. The menopause economy is consolidating around 2-3 major platforms per segment, with multiple business models coexisting and achieving venture-scale returns.
Sources & citations →
References Astellas Veozah. (2024). "FDA Approval and Revenue Data." Bayer Lynkuet. (October 2025). "FDA Approval and Peak Sales Forecast." Gedeon Richter Ryeqo. (2025). "NHS Approval and Revenue Data." Pfizer Myfembree. (2024). "FDA Approval and Market Data." Midi Health. (2026). "Series D Announcement and Clinical Outcomes." Gennev. (2024). "Aetna Coverage and Menopause Care." Elektra Health. (January 2026). "HelloMeno ACA Health Plan Launch." Alloy Women's Health. (2024). "Series A Funding and Personalized HRT." Evernow. (2025). "Clearblue Partnership and HRT Delivery." Stripes Beauty. (2024). "Menopause Products and Celebrity Backing." Wile. (2024). "Perimenopause Supplements and Seed Funding." Valerie. (May 2025). "Pre-seed Funding Announcement." Perelel. (2024). "Life-Stage Nutrition and Series Funding." Timeline. (2024). "Mitochondrial Longevity and Series D Funding." Embr Labs. (2024). "Wearable Thermal Therapy for Hot Flashes." Hormona. (May 2025). "Seed Funding and Hormone Testing Data." Hertility. (May 2025). "Series A Funding and 10-Hormone Panel." Oova. (2023). "Series A Funding and Quantitative Hormone Testing." Mira Care. (2025). "Hormone Testing and Oura Integration." Evela Health. (2025). "Employer Menopause Benefits Platform." Peppy. (2024). "Enterprise Menopause and Fertility Benefits." Maven Clinic. (2025). "Full-Stack Women's Health Platform." InsideTracker. (2024). "Biological Age Testing and Wearable Integration." Oura Ring. (2024). "Sleep, HRV, and Menopause Monitoring." Apple Watch. (2024). "Cycle Tracking and Cardiovascular Monitoring."